Shockwave Medical, Inc.

Ladies and gentlemen, thank you for standing by and welcome to the Shockwave Medical Inc. 3rd Quarter 2021 Earnings Conference Call. At this time, all participants are in listen-only mode. Later, we will conduct a question and answer session, and if you would like to ask a question during that time, simply press star 1 on your telephone keypad. If anyone should require assistance during the conference, please press star 0. I would now like to turn the conference over to our speaker today, Debbie Custer, Investor Relations. Please go ahead.

Thank you all for participating in today's call. Joining me today from Shockwave Medical are Doug Gottschall, President and Chief Executive Officer, Isaac Zacharias, Chief Commercial Officer, and Dan Puckett, Chief Financial Officer. Earlier today, Shockwave released financial results for the quarter ended September 30th, 2021. A copy of the press release is available on Shockwave's website. Before we begin, I would like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions of future events, results, or performance are forward-looking statements. All forward-looking statements, including without limitation statements relating to our sales and operating trends, business and hiring prospects, financial and revenue expectations, and future product development and approvals are based upon our current estimates and various assumptions. These statements involve material risks and uncertainties, including the impact of the COVID-19 pandemic that could cause actual results or events to material differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. For a list and description of the risks and uncertainties associated with our business, Please refer to the risk factor section of our annual report on Form 10-K on file with SEC and available on EDGAR and in our other reports filed periodically with the SEC. Shockwave disclaims any intention or obligation except as required by law to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise. The conference call contains time-sensitive information and is accurate only as of the live broadcast today, November 8, 2021. And with that, I'll turn the call over to Doug. Thank you.

Thanks, Debbie, and good afternoon, everyone. Welcome to our third quarter call. Hold on a second. We reported $65.2 million in revenue for the third quarter of 2021, representing an increase of 233% from the same period in 2020. Our C2 product once again led our growth as penetration and utilization continued at a healthy pace despite the challenges of COVID and the Delta variant. Isaac will provide additional color regarding the various dynamics that impacted the third quarter, but we are encouraged to see the waning of COVID's impact in hospitals in the U.S. Hopefully, we're finally past the elective procedure freeze and thaw cycle, which would certainly be a blessing for our customers and their patients. Factoring in the combination of continued traction of C2 and steady elective procedure recovery, but still anticipating some impact on procedure volumes from COVID and staffing shortages, We expect to finish 2021 with revenues in the range of $227 to $228 million. This translates into a growth rate of 235% to 236% over 2020. To provide additional perspective on what we're seeing from the commercial side, I will turn the call over to Isaac, and then Dan and I will share more details on the broader business and financial results from the quarter. Isaac?